| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSMB5 |
| Uniprot No | P28074 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 60-263aa |
| 氨基酸序列 | MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSMTTTLAFKFRHGVI VAADSRATAGAYIASQTVKKVIEINPYLLGTMAGGAADCSFWERLLARQC RIYELRNKERISVAAASKLLANMVYQYKGMGLSMGTMICGWDKRGPGLYY VDSEGNRISGATFSVGSGSVYAYGVMDRGYSYDLEVEQAYDLARRAIYQA TYRDAYSGGAVNLYHVREDGWIRVSSDNVADLHEKYSGSTP |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于PSMB5重组蛋白的典型参考文献示例(部分为模拟文献，供参考)：
---
1. **"Proteasome subunit β5i (PSMB5) mutations confer resistance to proteasome inhibitors in multiple myeloma"**
- **作者**: Lu et al.
- **摘要**: 研究通过基因测序发现PSMB5突变(如Cys63Phe)可导致多发性骨髓瘤对硼替佐米(Bortezomib)的耐药性，重组PSMB5蛋白实验证实突变体降低药物与蛋白酶体的结合能力。
2. **"Structural insights into the 20S proteasome and its interaction with PSMB5-targeting inhibitors"**
- **作者**: Huber et al.
- **摘要**: 利用X射线晶体学解析含重组PSMB5的蛋白酶体结构，揭示其与抑制剂(如卡非佐米)结合的分子机制，为优化抗肿瘤药物提供结构基础。
3. **"Overexpression of PSMB5 in leukemia cells correlates with poor prognosis and chemoresistance"**
- **作者**: Chen et al.
- **摘要**: 通过重组PSMB5蛋白表达实验，发现其在白血病细胞中的过表达导致蛋白酶体活性增强，并通过NF-κB通路促进细胞存活和耐药性。
4. **"PSMB5 as a biomarker for proteasome activity: Development of a recombinant protein-based assay"**
- **作者**: Zhang et al.
- **摘要**: 构建重组PSMB5蛋白并开发高通量检测方法，用于评估蛋白酶体抑制剂在肿瘤细胞中的靶向效率及药物筛选。
---
**说明**：以上文献为示例，实际研究中需通过PubMed、Web of Science等数据库检索真实文献。PSMB5相关研究多聚焦于其在蛋白酶体功能、肿瘤耐药性及抑制剂开发中的作用。
**Background of PSMB5 Recombinant Protein**
PSMB5 (Proteasome 20S Subunit Beta 5) is a critical component of the 20S proteasome core particle, a multisubunit protease complex responsible for degrading ubiquitinated proteins in the ubiquitin-proteasome system (UPS). As part of the β-subunit family, PSMB5 harbors chymotrypsin-like activity, cleaving peptide bonds after hydrophobic residues, and plays a central role in maintaining cellular protein homeostasis, regulating processes such as cell cycle progression, apoptosis, and stress responses.
Dysregulation of PSMB5 is implicated in various diseases, particularly cancers, where overexpression correlates with resistance to proteasome inhibitors (e.g., bortezomib) used in treating multiple myeloma and mantle cell lymphoma. This resistance often arises from mutations in PSMB5 or altered proteasome assembly, highlighting its significance as a therapeutic target.
Recombinant PSMB5 protein is produced using heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cells*) to study its structure, function, and interactions. Its purified form enables *in vitro* assays to investigate proteasomal activity, inhibitor binding mechanisms, and drug resistance profiles. Additionally, recombinant PSMB5 facilitates structural studies (e.g., X-ray crystallography) to design next-generation inhibitors with improved specificity and reduced off-target effects.
Research on PSMB5 recombinant protein also extends to understanding autoimmune disorders and neurodegenerative diseases linked to UPS dysfunction. By dissecting its role in pathological and physiological contexts, scientists aim to develop targeted therapies modulating proteasomal activity, offering potential breakthroughs in precision medicine.
×
